2023
International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance
Tan W, Contieri R, Buffi N, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat A. International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance. Journal Of Urology 2023, 210: 763-770. PMID: 37535836, DOI: 10.1097/ju.0000000000003639.Peer-Reviewed Original ResearchTransurethral resection of bladder tumorResection of bladder tumorNonmuscle-invasive bladder cancerTransurethral resectionBladder tumorsActive surveillanceBladder cancerScoring systemNonmuscle-invasive bladder cancer patientsAbsence of gross hematuriaMultivariate Cox proportional hazards analysisRisk factorsNonmuscle-invasive bladder tumorsNegative urinary cytologyCox proportional hazards analysisMedian follow-upMultivariate Cox regressionBladder cancer patientsProportional hazards analysisUrinary cytologyGross hematuriaT stageLandmark time pointsFollow-upCox regressionReply to Arnulf Stenzl, Morgan Rouprêt, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193–4
Heer R, Tan W, Gravestock P, Vadiveloo T, Lewis R, Penegar S, Vale L, MacLennan G, Hall E, Team P. Reply to Arnulf Stenzl, Morgan Rouprêt, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193–4. European Urology 2023, 85: 309-312. PMID: 37330372, DOI: 10.1016/j.eururo.2023.05.040.Peer-Reviewed Original Research
2022
A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E
Tan W, Bello A, Alvarez C, Guerrero-Ramos F, González-Padilla D, Nzeh C, de la Morena J, de Torres I, Hendricksen K, Goizueta F, Del Álamo J, Chiancone F, Fedelini P, Poggio M, Porpiglia F, Rodríguez V, Torres J, Wilby D, Robinson R, Sousa-Escandón A, Mata J, Moreno J, Molina F, Semino M, Stemberger A, Escudero J, Redorta J, Tan W. A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E. Bladder Cancer 2022, 8: 379-393. PMID: 38994184, PMCID: PMC11181696, DOI: 10.3233/blc-220026.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerTransurethral resection of bladder tumorRecurrence-free survivalProgression-free survivalInvasive bladder cancerMitomycin CBCG-naiveBladder cancerAdverse eventsTreated with intravesical bacillus Calmette-GuerinTreatment of non-muscle invasive bladder cancerIntravesical bacillus Calmette-GuerinResection of bladder tumorTreating non-muscle invasive bladder cancerFavorable adverse event profileAdverse event profileBacillus Calmette-GuerinMinor adverse eventsMulti-institutional studyBCG failurePapillary diseaseTransurethral resectionBladder tumorsConsecutive patientsMedian age
2016
Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia
Tan W, Rodney S, Lamb B, Feneley M, Kelly J. Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer Treatment Reviews 2016, 47: 22-31. PMID: 27231966, DOI: 10.1016/j.ctrv.2016.05.002.Peer-Reviewed Original ResearchConceptsNon-muscle invasive bladder cancerBladder cancerAnalysis of guidelinesBladder cancer casesUnited StatesCancer casesInvasive bladder cancerIntravesical treatmentTransurethral resectionExpensive cancerTreatment modalitiesSurveillance protocolsContemporary guidelinesUnited KingdomGuidelinesIntensive treatmentBladderCancerInternational ConsultationTreatmentConsultationUnits